TRGT - Targacept, Inc.

Targacept, Inc. (TRGT) was a biopharmaceutical company that focused on the discovery and development of novel therapies for the treatment of various neurological and psychiatric disorders. The company's research and development efforts were focused on the nicotinic acetylcholine receptor (nAChR) target class, which is involved in a variety of neurological and psychiatric processes.

In 2015, the company was acquired by Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company that focuses on developing treatments for rare bleeding disorders and other serious medical conditions.

Investors should note that investing in biopharmaceutical companies such as TRGT carries market risks, as the financial performance of the company is linked to a variety of factors, including the success of its clinical trials, regulatory approvals, competition, and changes in healthcare policies and regulations. Additionally, the biopharmaceutical industry is subject to significant research and development costs, and the success of a company's products is often uncertain until clinical trials are completed.

Investors should carefully consider these risks before investing in TRGT and consult with a financial advisor to determine if it is an appropriate investment for their portfolio. They should also review the company's financial statements and other public disclosures to gain a better understanding of its financial performance and risks.